Hardwick Julia
University Hospitals, Bristol NHS Foundation Trust.
Br J Nurs. 2012;21(9):S13-7. doi: 10.12968/bjon.2012.21.Sup6.S13.
Cabazitaxel, a new-generation taxane that fulfils a hitherto unmet need for second-line chemotherapy in metastatic castrate-resistant prostate cancer, has received approval from the European Medicines Agency. In a recent phase III clinical trial, this drug showed a survival benefit over mitoxantrone; however, it was associated with significant side effects, most notably neutropenia, diarrhoea, nausea/vomiting, peripheral neuropathy and fatigue. Careful patient selection for cabazitaxel is essential, as is a robust management plan for the detection, assessment and prompt treatment of any side effects. This article examines the nurse's role in patient preparation, education, ongoing monitoring and support throughout cabazitaxel treatment.
卡巴他赛是一种新一代紫杉烷类药物，满足了转移性去势抵抗性前列腺癌二线化疗迄今未被满足的需求，已获得欧洲药品管理局的批准。在最近的一项III期临床试验中，这种药物显示出比米托蒽醌更显著的生存获益；然而，它也伴有明显的副作用，最显著的是中性粒细胞减少、腹泻、恶心/呕吐、周围神经病变和疲劳。对卡巴他赛进行仔细的患者选择至关重要，对于任何副作用的检测、评估和及时治疗，制定一个强有力的管理计划同样重要。本文探讨了护士在卡巴他赛治疗全过程中患者准备、教育、持续监测和支持方面的作用。
